Xcout IntelEnlivex Ltd. competitors & alternatives
The 12 closest competitors and alternatives to Enlivex Ltd. among biotech companies — ranked by similarity to what Enlivex Ltd. actually does, not by market-cap band.
Subscribe to see Enlivex Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Enlivex Ltd.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Enlivex Ltd. at a glance
Enlivex Ltd. is a biotech company headquartered in Ness Ziona, Israel. It is publicly listed (ENLV) with a market capitalisation of $5.1M. Xcout tracks 19 named people at Enlivex Ltd., including Oren Hershkovitz (Chief Executive Officer).
Enlivex Ltd. leadership
- Oren HershkovitzChief Executive Officer
- Oren Hershkovitz, Ph.D.Chief Executive Officer
- Veronique Amor-BaroukhChief Operating Officer
- Veronique Amor-Baroukh, Ph.D.Chief Operating Officer
- Shachar ShlosbergerChief Financial Officer
- Einat GalamidiChief Medical Officer
13 more named people on record for Enlivex Ltd., with roles, board committees and tenure — see the full roster →
Top 12 Enlivex Ltd. competitors
Ranked by semantic similarity — how close each company is to Enlivex Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Carisma Therapeutics is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on discovering and developing engineered macrophage-based immunotherapies.
Similar biotech company
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Biotechnology
Kadimastem Ltd. is a clinical-stage cell therapy company headquartered in Ness Ziona, Israel, focused on developing advanced cell-based therapeutic treatments.
Similar biotech company
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Biotechnology
Efranat Ltd. is a biotechnology company based in Rehovot, Israel, established in 2009 to develop an anticancer immunotherapy treatment. The company has focused on developing a patent-protected formula utilizing Vitamin D binding protein macrophage-activating factor to enhance clinical stability and use.
Similar biotech company
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
Biotechnology
Inotrem is a French clinical-stage biotechnology company developing therapies for dysregulated innate immune responses and inflammation. Its lead candidate, nangibotide (LR12), targets TREM-1 and has been investigated for severe sepsis and other acute inflammatory conditions, serving patients with life-threatening immune-mediated diseases.
Similar biotech company
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Similar biotech company
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Similar biotech company
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Similar biotech company
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Biotechnology
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Enlivex Ltd. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Enlivex Ltd.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →